The primary aims were to evaluate the superiority of brodalumab over placebo at week @ with respect to at least a @ % reduction in the psoriasis area-and-severity index score ( PASI @ ) and a static physician 's global assessment ( sPGA ) score of @ or @ ( clear or almost clear skin ) , as well as the superiority of brodalumab over ustekinumab at week @ with respect to a @ % reduction in PASI score ( PASI @ ) .